Antengene Advances Cancer Treatment with Promising Preclinical Research on ATG-037
Antengene has published a groundbreaking preclinical research paper highlighting the efficacy of its CD73 small molecule inhibitor ATG-037 in combination with Selinexor for cancer gene therapy. This innovative approach could significantly enhance treatment options for various cancer types.